John Campbell: Ivermectin and mebendazole, 84% benefit in cancer

Key Takeaways

• Ivermectin + Mebendazole combination showed 84.4% clinical benefit (regression/stability) in cancer patients across multiple cancer types.
• Protocol used: 25mg Ivermectin + 250mg Mebendazole daily for 90 days (compounded capsules).
• No significant dose-response relationship found – lower doses may be equally effective.
• Side effects were mild (mostly gastrointestinal) with 94% of affected patients continuing treatment.
• Costs ~$1,000/year vs $111,000/year for standard chemotherapy.

Supplements & Protocols Mentioned

• Ivermectin: 25mg daily dose
• Mebendazole: 250mg daily dose
• Combined in single oral capsule taken for 90 days

Notable Quotes

“84.4% of patients did well, which is incredible… these drugs are remarkably inexpensive, remarkably cheap.”

Bottom Line

Cancer patients may consider discussing the Ivermectin + Mebendazole protocol (25mg/250mg daily) with their healthcare provider as a potential low-cost, low-toxicity adjunct therapy.

Watch the Full Video